Company to host conference call and webcast at 8:30am ET NEW YORK, March 21, 2024 /PRNewswire/ -- DarioHealth Corp. (Nasdaq: DRIO), a leader in the global digital therapeutics (DTx) market, announced today that it will release its financial results for the 4th quarter ended December 31, 2023, on Thursday, March 28th, 2024, before the market opens and will host a conference call and webcast at 8:30 am Eastern Time. Erez Raphael, Chief Executive Officer and Rick Anderson, President, will host the call. Confer ...

Study presented at ATTD 2024 is the first of a planned series examining the impact of Dario's integrated cardiometabolic solution as a means to address weight and diabetes with or without a GLP-1 Additional research presented demonstrated Dario's ability to improve awareness of the importance of flu vaccines in member with Type 2 diabetes NEW YORK, March 12, 2024 /PRNewswire/ -- DarioHealth Corp. (Nasdaq: DRIO) (the "Company"), a leader in the global digital therapeutics (DTx) market, announced today two ne ...

NEW YORK, Feb. 28, 2024 /PRNewswire/ -- DarioHealth Corp. (Nasdaq: DRIO), a leader in the global digital health market, today announced that management will participate in the Cowen 44th Annual Healthcare Conference, which is being held March 4-6, 2024, at the Boston Marriott Copley Place in Boston, Massachusetts. Erez Raphael, Chief Executive Officer, and Rick Anderson, President, will participate in a fireside chat on Wednesday, March 6th, from 10:30 – 11:00 AM ET. A live webcast of the event will be avai ...

Expecting nearly doubling Dario's pro forma revenues in 2023 Acquisition is immediately accretive to revenue and gross margins and expected to accelerate path to profitability Concurrent with the acquisition Dario prices $22.4 million equity financing Company to host conference call today at 8:30am ET. Dial-in and replay information below NEW YORK, Feb. 21, 2024 /PRNewswire/ -- DarioHealth Corp. (Nasdaq: DRIO) ("Dario" or the "Company") announced today that it has acquired Twill, Inc. ("Twill"), a leader in ...

DarioHealth Corp. (NASDAQ:DRIO) Q3 2023 Earnings Conference Call November 2, 2023 8:30 AM ET Company Participants Glenn Garmont - Investor Relations Erez Raphael - Chief Executive Officer Rick Anderson - President Conference Call Participants Charles Rhyee - TD Cowen Rahul Rakhit - Lifesci Operator Greetings, and welcome to the DarioHealth Third Quarter 2023 Results Conference Call. [Operator Instructions] As a reminder, this conference is being recorded. Thank you. It is now my pleasure to introduce your h ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File No. 001-37704 DarioHealth Corp. | (Exact name of registrant as specified in its charter) | | | --- | --- | | Delaware | ...

Financial Data and Key Metrics Changes - Revenues for Q2 2023 were $6.15 million, a decrease from $6.8 million in Q2 2022, attributed to delays with a strategic partner [6][12] - Pro forma gross margin improved to 51.5% in Q2 2023 from 36.1% in Q2 2022, driven by a shift from B2C to B2B revenue [17] - Non-GAAP operating loss reduced to $7.5 million in Q2 2023 from $11.1 million in Q2 2022 [38] Business Line Data and Key Metrics Changes - B2B revenue accounted for approximately 63% of total revenue in Q2 2023, reflecting a strategic shift towards the B2B market [18] - B2C revenue remained consistent with the previous two quarters, allowing the company to maintain a self-funded innovation platform [19] - The company has achieved 10 consecutive quarters of growth in recurring B2B2C revenue [24][34] Market Data and Key Metrics Changes - The partnership with Sanofi has been enhanced to strengthen strategic alignment and accelerate revenue share [2][25] - The Aetna partnership is expected to expand from a population of 10 million to approximately 30 million lives, increasing revenue opportunities [40] - The company anticipates additional health plans through partners like Solera, contributing to revenue growth in late 2023 and 2024 [21][44] Company Strategy and Development Direction - The company is transitioning to a multi-tenant Software-as-a-Service model for the healthcare industry, focusing on partnerships to drive growth [12][34] - The strategy emphasizes a consumer-first approach with a multi-chronic condition platform, validated by real-world data [15][36] - The company aims for an average gross margin of 70% by 2024, leveraging its B2B focus [17] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the business model despite current revenue scaling challenges, citing strong consumer traction and market fit [33][34] - The company expects B2C revenue to grow throughout the year, albeit at a slower rate than initially anticipated due to delays with Aetna and Sanofi [22] - Management highlighted the increasing focus on cost and ROI among customers in the current macroeconomic environment [21][78] Other Important Information - The company maintains a strong cash position of $52.6 million, providing a runway through 2025 [38] - The partnership with Sanofi is expected to expand beyond the current $30 million contract, indicating a strong future growth potential [25] Q&A Session Summary Question: Can you provide details on the process that led to the expansion of the partnership? - The expansion involves increasing conditions covered and expanding populations, with ongoing conversations for existing customers [29] Question: What is the potential revenue impact from the expanded partnership with the large regional health plan? - The revenue opportunity is expected to increase by about 20% due to the expanded membership [68][70] Question: What is the current state of the employer market? - The economy is impacting organizations differently, with some facing pressure due to high medical renewal rates, which are affecting decision-making [77][78] Question: How is AI being utilized in the business? - The company has been using AI for personalization and recommendations, which enhances user engagement and improves outcomes [79][80]

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File No. 001-37704 DarioHealth Corp. | (Exact name of registrant as specified in its charter) | | | --- | --- | | Delaware | 45-29 ...

DarioHealth Corp. (NASDAQ:DRIO) Q1 2023 Earnings Conference Call May 11, 2023 8:30 AM ET Company Participants Chuck Padala - Managing Director, Investor Relations Erez Raphael - Chief Executive Officer Rick Anderson - President Conference Call Participants Alex Nowak - Craig-Hallum Capital Group Charles Rhyee - Cowen Rahul Rakhit - LifeSci Capital Benjamin Haynor - Alliance Global Partners David Grossman - Stifel Financial Operator Good morning, and welcome to the DarioHealth First Quarter 2023 Results Call ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File No. 001-37704 DarioHealth Corp. | (Exact name of registrant as specified in its charter) | | | | --- | --- | --- | | Delawar ...